Xvivo Perfusion AB (publ) (STO:XVIVO)
Sweden · Delayed Price · Currency is SEK 197.40
-2.80 (-1.40%)
Aug 1, 2025, 5:29 PM CET
Intra-Cellular Therapies Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 822.93 | 822.42 | 597.54 | 415.29 | 258.39 | 179.86 | Upgrade | |
Revenue Growth (YoY) | 17.78% | 37.63% | 43.89% | 60.72% | 43.66% | -18.55% | Upgrade |
Cost of Revenue | 206.83 | 206 | 152.43 | 118.34 | 70.11 | 50.13 | Upgrade |
Gross Profit | 616.09 | 616.42 | 445.11 | 296.96 | 188.28 | 129.73 | Upgrade |
Selling, General & Admin | 390.75 | 379.77 | 309.21 | 223.38 | 153.38 | 107.71 | Upgrade |
Research & Development | 154.05 | 148.33 | 135.94 | 69.34 | 54.04 | 66.74 | Upgrade |
Other Operating Expenses | 0.66 | -1.09 | -5.43 | -0.22 | -0.39 | -0.53 | Upgrade |
Operating Expenses | 545.46 | 527.01 | 439.72 | 292.5 | 207.02 | 173.92 | Upgrade |
Operating Income | 70.64 | 89.41 | 5.4 | 4.45 | -18.74 | -44.19 | Upgrade |
Interest Expense | -52.3 | -1.26 | -1.19 | -0.61 | -0.28 | -0.36 | Upgrade |
Interest & Investment Income | 6.92 | 17.16 | 8.85 | 2.12 | - | 0.08 | Upgrade |
Currency Exchange Gain (Loss) | 32.39 | 32.39 | 9.69 | 17.09 | 5.98 | -12.6 | Upgrade |
Other Non Operating Income (Expenses) | 63.04 | 63.04 | 72.78 | -0.49 | 19.75 | -0.2 | Upgrade |
EBT Excluding Unusual Items | 120.68 | 200.73 | 95.52 | 22.58 | 6.71 | -57.26 | Upgrade |
Gain (Loss) on Sale of Assets | -0.78 | -0.78 | -1 | -0.26 | -0.04 | - | Upgrade |
Pretax Income | 119.9 | 199.95 | 94.52 | 22.31 | 6.67 | -57.26 | Upgrade |
Income Tax Expense | 8.52 | 27.77 | 2.7 | 3.89 | -1.49 | -13.53 | Upgrade |
Net Income | 111.38 | 172.18 | 91.82 | 18.43 | 8.15 | -43.74 | Upgrade |
Net Income to Common | 111.38 | 172.18 | 91.82 | 18.43 | 8.15 | -43.74 | Upgrade |
Net Income Growth | -7.75% | 87.52% | 398.29% | 126.04% | - | - | Upgrade |
Shares Outstanding (Basic) | 31 | 31 | 30 | 30 | 29 | 27 | Upgrade |
Shares Outstanding (Diluted) | 32 | 32 | 30 | 30 | 29 | 27 | Upgrade |
Shares Change (YoY) | 3.38% | 5.73% | 1.39% | 2.04% | 6.49% | 1.39% | Upgrade |
EPS (Basic) | 3.54 | 5.47 | 3.07 | 0.62 | 0.28 | -1.61 | Upgrade |
EPS (Diluted) | 3.50 | 5.44 | 3.07 | 0.62 | 0.28 | -1.61 | Upgrade |
EPS Growth | -10.92% | 77.35% | 394.72% | 121.43% | - | - | Upgrade |
Free Cash Flow | -8.82 | 40.56 | 3.27 | 9.67 | -22.25 | -14.9 | Upgrade |
Free Cash Flow Per Share | -0.28 | 1.28 | 0.11 | 0.33 | -0.77 | -0.55 | Upgrade |
Gross Margin | 74.87% | 74.95% | 74.49% | 71.50% | 72.87% | 72.13% | Upgrade |
Operating Margin | 8.58% | 10.87% | 0.90% | 1.07% | -7.25% | -24.57% | Upgrade |
Profit Margin | 13.53% | 20.94% | 15.37% | 4.44% | 3.16% | -24.32% | Upgrade |
Free Cash Flow Margin | -1.07% | 4.93% | 0.55% | 2.33% | -8.61% | -8.28% | Upgrade |
EBITDA | 95.2 | 110.9 | 19.03 | 13.3 | -11.7 | -36.61 | Upgrade |
EBITDA Margin | 11.57% | 13.48% | 3.19% | 3.20% | -4.53% | -20.35% | Upgrade |
D&A For EBITDA | 24.57 | 21.5 | 13.64 | 8.85 | 7.04 | 7.58 | Upgrade |
EBIT | 70.64 | 89.41 | 5.4 | 4.45 | -18.74 | -44.19 | Upgrade |
EBIT Margin | 8.58% | 10.87% | 0.90% | 1.07% | -7.25% | -24.57% | Upgrade |
Effective Tax Rate | 7.11% | 13.89% | 2.86% | 17.42% | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.